RXRX
Market cap | $1.67 Billion |
---|---|
Enterprise Value | $1.33 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-1.58 |
Beta | 0.0 |
Outstanding Shares | 227,143,401 |
Avg 30 Day Volume | 4,278,982 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -5.09 |
---|---|
PEG | -8.24 |
Price to Sales | - |
Price to Book Ratio | 3.85 |
Enterprise Value to Revenue | 29.81 |
Enterprise Value to EBIT | -3.8 |
Enterprise Value to Net Income | -5 |
Total Debt to Enterprise | 0.04 |
Debt to Equity | 0.11 |
No data
No data
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patient...